Stockreport

Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration

Adverum Biotechnologies, Inc.  (ADVM) 
Last adverum biotechnologies, inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: adverum.gcs-web.com/investor-overview
PDF Screening closing ahead of expectations, with full enrollment now anticipated in 4Q 2025 (previously 1Q 2026)ARTEMIS topline data readout accelerated to 1Q 2027 REDW [Read more]